Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Announces Name Change to KALA BIO
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers KALA
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers KALA
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers KALA
Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers KALA
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers KALA
Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers KALA
Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers KALA
Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers KALA
Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers KALA
Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers KALA
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers KALA
Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers KALA
Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers KALA
Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers KALA
Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers KALA
Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers KALA
Kala Pharmaceuticals Announces Reverse Stock Split
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers KALA
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kala Pharmaceuticals, Inc.
Via Business Wire
Tickers KALA
Kala Pharmaceuticals Announces EYSUVIS® Now Covered by OptumRx
From Kala Pharmaceuticals, Inc.
Via Business Wire
Tickers KALA
Kala Pharmaceuticals to Present at Jefferies 2021 Virtual Healthcare Conference
From Kala Pharmaceuticals, Inc.
Via Business Wire
Tickers KALA
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kala Pharmaceuticals, Inc.
Via Business Wire
Tickers KALA
Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference
From Kala Pharmaceuticals, Inc.
Via Business Wire
Tickers KALA
Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
From Kala Pharmaceuticals, Inc.
Via Business Wire
Tickers KALA
Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call
From Kala Pharmaceuticals, Inc.
Via Business Wire
Tickers KALA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.